Tumor Biology

, Volume 34, Issue 4, pp 2299–2308

Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer

  • Zhongpeng Zhu
  • Baocheng Wang
  • Jingwang Bi
  • Cong Zhang
  • Yan Guo
  • Huili Chu
  • Xiuju Liang
  • Chen Zhong
  • Jun Wang
Research Article


HuR is an ubiquitously expressed RNA-binding protein that stabilizes messenger RNA and regulates translation. This protein has been shown to play an important role in carcinogenesis and cancer progression. P-glycoprotein (P-gp) is the product of the multidrug resistance 1 gene, and the overexpression of P-gp induces multidrug resistance and represents a major obstacle in cancer chemotherapy. The purpose of this study was to determine the expression of HuR and P-gp in human breast cancer tissues and analyze the relationship between HuR or P-gp expression and the clinical–pathological variables and patient outcomes. Immunohistochemistry was used to determine HuR and P-gp expression in 82 human breast cancer tissues and 20 matched adjacent noncancerous tissues. Additionally, 16 benign breast tumor samples were used as controls. The overexpression of cytoplasmic HuR was found in breast cancer but not in the matched adjacent noncancerous tissues or benign breast tumors. The expression levels of cytoplasmic HuR were significantly associated with increased age, high nuclear grade, and the positive expression of the ER, PR, and HER-2/neu. HuR was also associated with the expression of P-gp protein. Furthermore, univariate analysis indicates that patients with high expression levels of cytoplasmic HuR or P-gp had significantly reduced survival compared to patients with low expression levels. A multivariate analysis showed that age at diagnosis, nuclear grade, and cytoplasmic HuR positivity were independent indicators for disease-free survival and overall survival in patients with breast cancer. In conclusion, cytoplasmic HuR expression detected by immunohistochemical staining is a negative prognostic indicator for survival in patients with breast cancer.


HuR P-gp Breast cancer Prognosis 


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer. 2010;10:196–208.PubMedCrossRefGoogle Scholar
  3. 3.
    Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005;16:1723–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Hayes DF. Prognostic and predictive factors revisited. Breast. 2008;14:493–9.CrossRefGoogle Scholar
  5. 5.
    Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang J, Guo Y, Wang B, Bi J, Li K, Liang X, et al. Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep. 2012;39:11153–65.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang L, Shao ZM. Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Investig. 2006;24:581–7.CrossRefGoogle Scholar
  8. 8.
    Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA. 2010;1:214–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim MY, Hur J, Jeong S. Emerging roles of RNA and RNAbinding protein network in cancer cells. BMB Rep. 2009;42:125–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Hasegawa H, Kakuguchi W, Kuroshima T, Kitamura T, Tanaka S, Kitagawa Y, et al. HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells. Br J Cancer. 2009;100:1943–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J. 2000;19:2340–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Rajasingh J, Bord E, Luedemann C, Asai J, Hamada H, Thorne T, et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J. 2006;20:2112–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Sengupta S, Jang BC, Wu MT, Paik JH, Furneaux H, Hla T. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem. 2003;278:25227–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang J, Zhao W, Guo Y, Zhang B, Xie Q, Xiang D, et al. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology. 2009;76:420–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Stoppoloni D, Cardillo I, Verdina A, Vincenzi B, Menegozzo S, Santini M, et al. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer. 2008;113:2761–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 2003;63:7591–4.PubMedGoogle Scholar
  18. 18.
    Lim SJ, Lee SH, Joo SH, Song JY, Choi SI. Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. Cancer Res Treat. 2009;41:87–92.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang J, Wang B, Bi J, Zhang C. Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med Oncol. 2011; 28 (Suppl 1):S577–85.Google Scholar
  20. 20.
    Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun. 1989;165:1415–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Mealey KL, Barhoumi R, Burghardt RC, Safe S, Kochevar DT. Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells. Antimicrob Agents Chemother. 2002;46:755–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Rybárová S, Vecanová J, Hodorová I, Mihalik J, Čižmáriková M, Mojžiš J, et al. Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer. Med Sci Monit. 2011;17:BR354–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997;89:917–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocrinol Relat Cancer. 2003;10:43–73.CrossRefGoogle Scholar
  25. 25.
    Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol. 1995;6:679–85.PubMedGoogle Scholar
  26. 26.
    Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocrinol Relat Cancer. 2003;10:43–73.CrossRefGoogle Scholar
  27. 27.
    Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005;65:2157–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007;13:6959–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilén ST, Laakso M, et al. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol. 2011;224:529–39.PubMedCrossRefGoogle Scholar
  30. 30.
    Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006;66:7948–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Guo X, Wu Y, Hartley RS. Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. Mol Carcinog. 2010;49:130–40.PubMedGoogle Scholar
  32. 32.
    Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep. 2011;26:237–45.PubMedGoogle Scholar
  33. 33.
    Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res. 2011;31:303–10.PubMedGoogle Scholar
  34. 34.
    Griseri P, Bourcier C, Hieblot C, Essafi-Benkhadir K, Chamorey E, Touriol C, et al. A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients. Hum Mol Genet. 2011;20:4556–68.PubMedCrossRefGoogle Scholar
  35. 35.
    Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol. 2012;14:659–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 2009;6:575–83.PubMedCrossRefGoogle Scholar
  37. 37.
    Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, et al. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle. 2010;9:1354–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Xu F, Zhang X, Lei Y, Liu X, Liu Z, Tong T, et al. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J Cell Biochem. 2010;111:727–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, et al. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther. 2008;7:1496–506.PubMedCrossRefGoogle Scholar
  40. 40.
    Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, et al. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle. 2010;9:3337–46.PubMedCrossRefGoogle Scholar
  41. 41.
    Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem. 2011;286:41442–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S. Jet al. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res. 2008;6:1250–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 2009;69:4567–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, et al. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res. 2011;9:648–59.PubMedCrossRefGoogle Scholar
  45. 45.
    Serini S, Donato V, Piccioni E, Trombino S, Monego G, Toesca A, et al. Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR. J Nutr Biochem. 2011;22:874–85.PubMedCrossRefGoogle Scholar
  46. 46.
    Latorre E, Tebaldi T, Viero G, Spartà AM, Quattrone A, Provenzani A. Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer. 2012;11:13.PubMedCrossRefGoogle Scholar
  47. 47.
    Srikantan S, Abdelmohsen K, Lee EK, Tominaga K, Subaran SS, Kuwano Y, et al. Translational control of TOP2A influences doxorubicin efficacy. Mol Cell Biol. 2011;31:3790–801.PubMedCrossRefGoogle Scholar
  48. 48.
    Srikantan S, Tominaga K, Gorospe M. Functional interplay between RNA-binding protein HuR and microRNAs. Curr Protein Pept Sci. 2012;13:372–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Zhongpeng Zhu
    • 1
  • Baocheng Wang
    • 1
  • Jingwang Bi
    • 1
  • Cong Zhang
    • 2
  • Yan Guo
    • 3
  • Huili Chu
    • 1
  • Xiuju Liang
    • 1
  • Chen Zhong
    • 1
  • Jun Wang
    • 1
  1. 1.Department of OncologyGeneral Hospital, Jinan Command of People’s Liberation ArmyJinanChina
  2. 2.Department of RadiotherapyGeneral Hospital, Jinan Command of the People’s Liberation ArmyJinanChina
  3. 3.Department of OutpatientMilitary Command of Shandong ProvinceJinanChina

Personalised recommendations